Holen Sie sich die Stockscreener-App
1.58
3.95%
0.06
Handel nachbörslich:
1.58
Schlusskurs vom Vortag:
$1.52
Offen:
$1.52
24-Stunden-Volumen:
31,460
Relative Volume:
2.05
Marktkapitalisierung:
$84.49M
Einnahmen:
$118.18M
Nettoeinkommen (Verlust:
$5.99M
KGV:
11.98
EPS:
0.1319
Netto-Cashflow:
$-12.91M
1W Leistung:
+1.94%
1M Leistung:
+3.95%
6M Leistung:
-8.42%
1J Leistung:
-31.30%
1-Tages-Spanne:
$1.49
$1.59
1-Wochen-Bereich:
$1.48
$1.59
52-Wochen-Spanne:
$1.17
$2.62
Intercure Ltd Stock (INCR) Company Profile
Vergleichen Sie INCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.58 | 84.49M | 118.18M | 5.99M | -12.91M | 0.1319 |
|
ZTS
Zoetis Inc
|
147.37 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.53 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.12 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-05-18 | Hochstufung | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Aktie (INCR) Neueste Nachrichten
What analysts say about InterCure Ltd. stockFree Stock Selection - PrintWeekIndia
What drives InterCure Ltd. stock priceFree Predictions - PrintWeekIndia
Is InterCure Ltd. a good long term investmentHigh-impact stock picks - jammulinksnews.com
InterCure Ltd. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com
InterCure (NASDAQ:INCR) Shares Down 3.5% – Here’s What Happened - Defense World
What makes InterCure Ltd. stock price move sharply2x Return Forecast - newser.com
How InterCure Ltd. stock performs during market volatilityFree Access to Community - Newser
Why InterCure Ltd. stock attracts strong analyst attentionSmart Money Signals - Newser
InterCure (NASDAQ:INCR) Stock Price Up 1.9% – What’s Next? - Defense World
InterCure And Cookies Successfully Launch Flagship Pharmacy In Be'er Sheva, Israel - Barchart.com
InterCure (NASDAQ:INCR) Shares Down 4.4% – What’s Next? - Defense World
InterCure Reports FY2024 Results - mg Magazine
InterCure Reports Strong Start to 2025 Amid Recovery Efforts - TipRanks
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PR Newswire
Intercure Ltd. Delays Yearly Report Filing - TipRanks
Interbusiness, Virdis partner to distribute Intercure products - Rubber News
InterCure (NASDAQ:INCR) Stock Price Down 3.4% – Time to Sell? - Defense World
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - GuruFocus.com
InterCure (NASDAQ:INCR) Shares Down 0.7%What's Next? - MarketBeat
InterCure Announces Leadership Change and Secures $18.2 Million Financing - TipRanks
InterCure Secures Massive $48M War Recovery Fund: CEO Takes Helm in Strategic Leadership Shift - Stock Titan
Short Interest in InterCure Ltd. (NASDAQ:INCR) Expands By 96.2% - MarketBeat
Jane Street Group LLC Acquires New Stake in InterCure Ltd. (NASDAQ:INCR) - Defense World
InterCure (NASDAQ:INCR) Trading Up 3.7% – Should You Buy? - Defense World
Cannabis co InterCure raising NIS 66m for Nir Oz facilityGlobes - Globes - Israel Business News
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - PR Newswire
Synbiotic's CAGR Forecast at 80%, ECS Botanics to Expand Footprint in Germany, & More from Intercure - Business of Cannabis
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
InterCure nears break even in first half of 2024, despite ongoing Israel-Hamas war - Crain's Chicago Business
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewswire
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Yahoo Finance
IM Cannabis Merger Scrapped, Cel AI Gets a New CEO, & More from Intercure - Business of Cannabis
Analyst: Israel’s InterCure paving path to big gains - Green Market Report
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference - Business Wire
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
InterCure: Bargain Israel Cannabis Play (NASDAQ:INCR) - Seeking Alpha
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint - Business Wire
InterCure Provides Update Regarding Nir Oz Facility in Israel - Cannabis Business Times
InterCure Provides an Update Regarding Nir Oz Facility - GlobeNewswire
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain - GlobeNewswire
InterCure Wins Cannolam Arbitration Proceeding - Yahoo Finance
InterCure Ltd Issues Update Regarding the Security Situation in Israel By Investing.com - Investing.com UK
Finanzdaten der Intercure Ltd-Aktie (INCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):